$10.65
0.13[1.24%]
At close: May 31
$10.65
0[0.00%]
After Hours: 4:02PM EDT
Cellebrite DI
(NASDAQ:CLBT)Cellebrite DI Stock (NASDAQ:CLBT), Analyst Ratings, Price Targets, Predictions
Cellebrite DI Ltd has a consensus price target of $11.55, established from looking at the 31 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Needham, and Lake Street on May 24, 2024, May 24, 2024, and April 19, 2024. With an average price target of $13.67 between JP Morgan, Needham, and Lake Street, there's an implied 28.33% upside for Cellebrite DI Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Needham
Lake Street
Craig-Hallum
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cellebrite DI
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/24/2024 | Buy Now | 31.46% | JP Morgan | Brian Essex | $12 → $14 | Maintains | Overweight | Get Alert |
| 05/24/2024 | Buy Now | 31.46% | Needham | Mike Cikos | $13.5 → $14 | Maintains | Buy | Get Alert |
| 04/19/2024 | Buy Now | 22.07% | Lake Street | Frank Takkinen | → $13 | Initiates | → Buy | Get Alert |
| 04/01/2024 | Buy Now | 50.23% | Craig-Hallum | Jeff Van Rhee | $14 → $16 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | 22.07% | B of A Securities | Tal Liani | $12 → $13 | Maintains | Buy | Get Alert |
| 03/28/2024 | Buy Now | 26.76% | Needham | Mike Cikos | $13 → $13.5 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | — | William Blair | Jonathan Ho | — | Upgrade | Market Perform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | 12.68% | B of A Securities | Tomer Zilberman | → $12 | Upgrade | Neutral → Buy | Get Alert |
| 02/15/2024 | Buy Now | 22.07% | Needham | Mike Cikos | $10 → $13 | Maintains | Buy | Get Alert |
| 08/30/2023 | Buy Now | -6.1% | Needham | Mike Cikos | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | -6.1% | JP Morgan | Sterling Auty | $8 → $10 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | -6.1% | Needham | Mike Cikos | $7 → $10 | Maintains | Buy | Get Alert |
| 07/19/2023 | Buy Now | 3.29% | Craig-Hallum | Jeff Van Rhee | → $11 | Initiates | → Buy | Get Alert |
| 05/17/2023 | Buy Now | -34.27% | Needham | Mike Cikos | → $7 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | -34.27% | Needham | Mike Cikos | → $7 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | Buy Now | -34.27% | Needham | Mike Cikos | $6.5 → $7 | Maintains | Buy | Get Alert |
| 02/16/2023 | Buy Now | -38.97% | Needham | Mike Cikos | → $6.5 | Reiterates | → Buy | Get Alert |
| 08/12/2022 | Buy Now | -43.66% | B of A Securities | Tal Liani | $6.5 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2022 | Buy Now | -6.1% | Cowen & Co. | Shaul Eyal | $13 → $10 | Maintains | Outperform | Get Alert |
| 08/12/2022 | Buy Now | — | William Blair | Jonathan Ho | — | Downgrade | Outperform → Market Perform | Get Alert |
| 08/11/2022 | Buy Now | -38.97% | Needham | Mike Cikos | $6 → $6.5 | Maintains | Buy | Get Alert |
| 05/13/2022 | Buy Now | -6.1% | Deutsche Bank | Jamie Shelton | $11 → $10 | Maintains | Buy | Get Alert |
| 05/13/2022 | Buy Now | -43.66% | Needham | Mike Cikos | $9.5 → $6 | Maintains | Buy | Get Alert |
| 02/24/2022 | Buy Now | -1.41% | JP Morgan | Sterling Auty | → $10.5 | Initiates | → Overweight | Get Alert |
| 02/11/2022 | Buy Now | -1.41% | Deutsche Bank | Jamie Shelton | → $10.5 | Initiates | → Buy | Get Alert |
| 12/29/2021 | Buy Now | -10.8% | Needham | Mike Cikos | $12 → $9.5 | Maintains | Buy | Get Alert |
| 12/02/2021 | Buy Now | 3.29% | B of A Securities | Tal Liani | — | Initiates | → Buy | Get Alert |
| 10/21/2021 | Buy Now | 40.85% | Citigroup | Tyler Radke | — | Initiates | → Buy | Get Alert |
| 09/29/2021 | Buy Now | 12.68% | Needham | Mike Cikos | — | Initiates | → Buy | Get Alert |
| 09/24/2021 | Buy Now | — | William Blair | Jonathan Ho | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Cellebrite DI (CLBT)?
The latest price target for Cellebrite DI (NASDAQ: CLBT) was reported by JP Morgan on May 24, 2024. The analyst firm set a price target for $14.00 expecting CLBT to rise to within 12 months (a possible 31.46% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cellebrite DI (CLBT)?
The latest analyst rating for Cellebrite DI (NASDAQ: CLBT) was provided by JP Morgan, and Cellebrite DI maintained their overweight rating.
When was the last upgrade for Cellebrite DI (CLBT)?
The last upgrade for Cellebrite DI Ltd happened on March 13, 2024 when William Blair raised their price target to N/A. William Blair previously had a market perform for Cellebrite DI Ltd.
When was the last downgrade for Cellebrite DI (CLBT)?
The last downgrade for Cellebrite DI Ltd happened on August 12, 2022 when B of A Securities changed their price target from $6.5 to $6 for Cellebrite DI Ltd.
When is the next analyst rating going to be posted or updated for Cellebrite DI (CLBT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellebrite DI, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellebrite DI was filed on May 24, 2024 so you should expect the next rating to be made available sometime around May 24, 2025.
Is the Analyst Rating Cellebrite DI (CLBT) correct?
While ratings are subjective and will change, the latest Cellebrite DI (CLBT) rating was a maintained with a price target of $12.00 to $14.00. The current price Cellebrite DI (CLBT) is trading at is $10.65, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.